Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention
Research output: Contribution to journal › Journal article › Research › peer-review
Terlipressin is a vasopressin analogue used for its potent V1a effects in cirrhotic patients. Recent data suggest that terlipressin has affinity to renal V2 receptors and modulates Aquaporin 2 (AQP2) expression and free water clearance. Stimulation of renal V2 receptors may also affect sodium transport via the Epithelial Sodium Channel (ENaC). Furthermore, endothelial V2 receptors may indirectly affect proximal sodium handling by increasing plasma cAMP.
| Original language | English |
|---|---|
| Journal | Scandinavian Journal of Clinical & Laboratory Investigation |
| Volume | 71 |
| Issue number | 2 |
| Pages (from-to) | 112-6 |
| Number of pages | 5 |
| ISSN | 0036-5513 |
| DOIs | |
| Publication status | Published - Apr 2011 |
ID: 34106548